NIF-Guided RAMIE Using ICG Versus OTE Feasibility RCT

Launched by ST. JOSEPH'S HEALTHCARE HAMILTON · Jun 23, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new surgical method for treating esophageal cancer called Robotic Assisted Minimally Invasive Esophagectomy (RAMIE). This technique uses advanced robotic technology to perform surgery with smaller incisions, which may lead to less pain and a quicker recovery compared to the traditional Open Transthoracic Esophagectomy (OTE), a more invasive procedure known for its high complication rates. The goal of this trial is to gather information and prepare for a future study that will directly compare RAMIE to OTE in patients with early to mid-stage esophageal cancer.

To be eligible for this trial, participants need to be at least 18 years old and diagnosed with clinical Stage I, II, or III esophageal cancer. They should also be considered suitable candidates for minimally invasive surgery, as determined by their surgeon. However, individuals who are pregnant, breastfeeding, or have Stage IV esophageal cancer will not be able to participate. If you join the trial, you can expect to receive care from a team of experts and contribute to valuable research that could improve surgical options for esophageal cancer patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 or older
• • Clinical Stage I, II, or III esophageal cancer, who are candidates for surgery after discussion in multidisciplinary tumor board.
• • Candidates for minimally invasive surgery as determined by the operating surgeon.
• Exclusion Criteria:
• • Hypersensitivity or allergy to ICG, sodium iodide, or iodine
• • Women who are currently pregnant or are breastfeeding; or women of childbearing potential who are not currently taking adequate birth control
• • Clinical Stage IV esophageal cancer.
• • Not a candidate for minimally invasive surgery as determined by the operating surgeon.